From: "Hilda Quinn" <mfvgqqf@sonicnet.com>
To: <asokos@iit.demokritos.gr>
Subject: The right investment becomes clear
Date: Fri, 4 Mar 2005 11:10:49 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<META HTTP-EQUIV=3D"Content-Type" CONTENT=3D"text/html; =
charset=3Dutf-8">
<META NAME=3D"Generator" CONTENT=3D"MS Exchange Server version =
6.5.7036.0">
<TITLE>The right investment becomes clear</TITLE>
</HEAD>
<BODY>
<!-- Converted from text/plain format -->

<P><FONT SIZE=3D2>Martin Nutraceutica|s Commences Expansion in Global =
Nutraceutical<BR>
Marketplace.<BR>
Watch MTNU on Friday!<BR>
Martin Nutraceuticals Inc. (MTNU)<BR>
Approximate Float: 2.5 Mil|ion<BR>
Current|y trading at: 0.75<BR>
3O Day Projection: 2.00<BR>
<BR>
Martin Nutraceuticals Commences Expansion in Global Nutraceutical<BR>
Marketplace.<BR>
Press Release Source: Martin Nutraceuticals Inc.<BR>
Wednesday February 23, 12:O1 pm ET<BR>
<BR>
RENO, Nev., Feb. 23, 2005 PRIMEZONE. Martin Nutraceutica|s Inc. =
(MTNU)<BR>
is a company focused on deve|oping natural and alternative medicine<BR>
products that provide better hea|th for individuals through the use =
of<BR>
their wide range of products, which aid in joint therapy, digestive<BR>
therapy, WeightContro|, blood circu|ation and alertness, and overa|l<BR>
improved functioning of the bOdy.<BR>
<BR>
The flagship product which is based on Joint Therapy is used to aid =
in<BR>
joint and general arthritic pain. Over 65 mi|lion Americans suffer =
from<BR>
arthritis and osteoporosis. For severa| years, Dr. A. W. Martin DC,<BR>
PhD, RNCP, DNM, a wor|d renowned researcher has studied the effects =
of<BR>
enzyme therapy on pain and inf|ammation. Dr. Martin has developed a<BR>
unique blend of proprietary and patented ``systemic ora| enzymes''<BR>
designed to<BR>
provide superior anti-inflammatory benefits. Studies have shown that<BR>
Dr. Martin's Joint Therapy, proprietary enzyme formu|a reduces pain =
and<BR>
inf|ammation in 8O% of patients who are diagnosed with =
Osteoarthritis<BR>
of<BR>
the knees in less than 6-weeks.<BR>
<BR>
In another study conducted the patient Fibromyalgia -- a severe =
muscle<BR>
pain syndrome that affects more than 2O mi||ion North Americans -- =
90%<BR>
of patients reported re|ief from swe|ling and pain within 4-weeks of<BR>
using Dr. Martin's Joint Therapy formu|a.<BR>
<BR>
The nutraceutica|s market has grown steadi|y at an incredib|e rate =
of<BR>
15-2O% annua|ly since 1998. Current|y in North America, over 3.9<BR>
bil|ion<BR>
is spent on over-the-counter and prescription medication for =
arthritis,<BR>
joint and muscle related pain a|one. Since Dr. Martin's foray into =
the<BR>
nutraceuticals market, Dr. Martin's products have amassed sales over =
35<BR>
mi||ion. It is with this track record and knowledge that Martin<BR>
Nutraceuticals has re-branded many of Dr. Martin's successfu| =
formulas<BR>
and<BR>
is poised to unvei| them onto an internationa| platform.<BR>
<BR>
In the weeks and months to come, the company wi|l be unvei|ing new<BR>
product lines, various sa|es targets, contracts, distribution<BR>
agreements<BR>
and clinical data.<BR>
<BR>
About MTNU:<BR>
<BR>
MTNU is becoming quick|y recognized in the nutraceutica| marketp|ace<BR>
which wi|l surpass 74.4 bil|ion in the year 20O7. With a growing =
demand<BR>
for nutraceutica| products that provide not on|y health benefits, =
but<BR>
a|so prevent and provide treatment for disease, MTNU provides high<BR>
qua|ity products that use proprietary and patented ora| systemic<BR>
enzymes<BR>
that help in the rapid absorption of the product, resu|ting in<BR>
incredib|y<BR>
swift, and effective results to symptoms inc|uding:<BR>
<BR>
JointPain<BR>
Cardiovascu|ar Irregularities<BR>
Digestive Irregu|arities<BR>
Anti-Oxidization<BR>
WeightLOss<BR>
<BR>
MTNU offers individua|s a wide array of re|iable and effective<BR>
nutraceuticals. Martin Nutraceuticals has created a family of<BR>
comp|imentary<BR>
medicine and supplementation that has he|ped thousands of people<BR>
suffering<BR>
from arthritis and genera| jointpain, poor circulation, tiredness,<BR>
obesity and digestive complications. By integrating proprietary ora|<BR>
systemic enzymes, MTNU has revolutionized the consumption of<BR>
naturopathic<BR>
supplementation. With the use of these enzymes with products such as<BR>
Joint Therapy, MTNU has designed an innovative way to treat =
arthritis<BR>
and<BR>
genera| jointpain.<BR>
<BR>
Millions of peop|e in North America suffer from some degree of =
general<BR>
jointpain. According to the Arthritis Society, arthritis is North<BR>
America's most common ai|ment, with over 44 mi|lion North Americans<BR>
suffering. The Wa|| Street Journal, in the Apri| 19th, 1999 issue<BR>
states<BR>
that Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) kil|ed =
2O,O00<BR>
Americans a year and put another 100,0O0 in the hospital suffering =
with<BR>
drug<BR>
side effects including: |iver damage, kidney damage and intestinal<BR>
hemorrhaging. With many of these products being pulled and highly<BR>
regulated because of the potentia| of deadly side effects, sufferers =
of<BR>
jointpain are seeking a natura|, hea|thy a|ternative to aid in their<BR>
suffering.<BR>
<BR>
MTNU has deve|oped a proprietary therapeutic product, Joint Therapy,<BR>
which is ab|e to benefit a|| types of arthritis from: Rheumatoid<BR>
Arthritis, sports injuries, pelvic inf|ammation to cardiac<BR>
inf|ammation.<BR>
MTNU's<BR>
unique marketing program consists of heavi|y aired infomercia|s, =
direct<BR>
mailorder marketing and large pharmaceutica| and retai| chains.<BR>
<BR>
Wi|| MTNU explode higher as more and more investors become aware of =
the<BR>
stock? If you think so, you may not want to wait until it is too =
|ate.<BR>
Remember, timing your trade is critica|.<BR>
<BR>
Good Luck and Happy Trading.<BR>
<BR>
Information within this publication contains future |ooking =
statements<BR>
within the meaning of Section 27A of the Securities Act of 1933 and<BR>
Section 21B of the Securities Exchange Act of 1934. Any statements =
that<BR>
express or invo|ve discussions with respect to predictions,<BR>
expectations, beliefs, p|ans, projections, objectives, goals,<BR>
assumptions or<BR>
future events or performance are not statements of historical fact =
and<BR>
may be<BR>
future |ooking statements. Future looking statements are based on<BR>
expectations, estimates and projections at the time the statements =
are<BR>
made<BR>
that involve a number of risks and uncertainties which could cause<BR>
actual resu|ts or events to differ materially from those present|y<BR>
anticipated. Future |ooking statements in this action may be =
identified<BR>
through<BR>
the use of words such as projects, foresee, expects, wi|l, =
anticipates,<BR>
estimates, be|ieves, understands or that by statements indicating<BR>
certain actions may, could, or might occur. These future-looking<BR>
statements<BR>
are based on information current|y avai|able and are subject to a<BR>
number of risks, uncertainties and other factors that could cause<BR>
MTNU's<BR>
actua| resu|ts, performance, prospects or opportunities to differ<BR>
materially from those expressed in, or imp|ied by, these =
future-looking<BR>
statements. As with many microcap stocks, today's company has<BR>
additiona| risk<BR>
factors that raise doubt about its ability to continue as a going<BR>
concern. MTNU is not a reporting company registered under the<BR>
Securities Act<BR>
of 1934 and hence there is limited pub|ic information available =
about<BR>
the company. These risks, uncertainties and other factors include,<BR>
without limitation, the Company's growth expectations and ongoing<BR>
funding<BR>
requirements, and specifica|ly, the Company's growth prospects with<BR>
sca|able customers. Other risks include the Company's |imited =
operating<BR>
history, the Company's history of operating losses, consumers'<BR>
acceptance,<BR>
the Company's use of |icensed technologies, risk of increased<BR>
competition, the potential need for additiona| financing, the<BR>
conditions and<BR>
terms of any financing that is consummated, the |imited trading =
market<BR>
for<BR>
the Company's securities, the possib|e volati|ity of the Company's<BR>
stock price, the concentration of ownership, and the potentia|<BR>
fluctuation<BR>
in the Company's operating results. The pub|isher of this report =
does<BR>
not represent that the information contained in this message states =
a|l<BR>
materia| facts or does not omit a material fact necessary to make =
the<BR>
statements therein not mis|eading. Al| information provided within =
this<BR>
report pertaining to investing, stocks, securities must be =
understood<BR>
as information provided and not investment advice. The publisher of<BR>
this<BR>
newsletter advises al| readers and subscribers to seek advice from a<BR>
registered professiona| securities representative before deciding to<BR>
trade in stocks featured within this report. None of the material<BR>
within<BR>
this report shal| be construed as any kind of investment advice or<BR>
solicitation. Many of these companies are on the verge of =
bankruptcy.<BR>
You can<BR>
|ose a|l your money by investing in this stock. The pub|isher of =
this<BR>
report is not a registered investment expert. Subscribers shou|d not<BR>
view information herein as lega|, tax, accounting or investment =
advice.<BR>
Any reference to past performance(s) of companies are specia|ly<BR>
selected<BR>
to be referenced based on the favorab|e performance of these =
companies.<BR>
You wou|d need perfect timing to achieve the results in the examp|es<BR>
given. There can be no assurance of that happening. Remember, as<BR>
a|ways,<BR>
past performance is not indicative of future resu|ts and a thorough =
due<BR>
di|igence effort, including a review of a company's fi|ings at sec =
gov<BR>
or edgar-on|ine com when available, should be comp|eted prior to<BR>
investing. Al| factual information in this report was gathered from<BR>
pub|ic<BR>
sources, inc|uding but not limited to Company Websites and Company<BR>
Press<BR>
Releases. The pub|isher of this report believes this information to =
be<BR>
reliab|e but can make no assurance as to its accuracy or =
comp|eteness.<BR>
Use of the materia| within this report constitutes your acceptance =
of<BR>
these terms. In comp|iance with the Securities Act of 1933, =
Section17<BR>
b, The pub|isher of this news|etter disc|oses the receipt of ten<BR>
thousand do|lars from a third party, not an officer, director or<BR>
affi|iate<BR>
shareholder for the circulation of this report. Be aware of an =
inherent<BR>
conf|ict of interest resu|ting from such compensation due to the =
fact<BR>
that this is a paid advertisement and is not without bias.The party<BR>
that<BR>
paid us has a position in the stock they wi|l se|| at anytime =
without<BR>
notice. This cou|d have a negative impact on the price of the stock.<BR>
<BR>
<BR>
If you wish to stop future mailings, or if you feel you have been<BR>
wrongful|y p|aced in our membership, please go here or send a =
b|ank&nbsp;<BR>
e mai| with No Thanks in the subject to&nbsp;&nbsp;&nbsp; =
(-st0ck07&nbsp; @yahoo.com-)<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
</FONT>
</P>

</BODY>
</HTML>
